Pfizer Vaccine Shows Promise for Children from 5 to 11 Years Old, UAB Experts Say
Pfizer released trial results Monday of a COVID vaccine for children ages 5 to 11 that uses one-third the dosage given adults, a move one pediatric expert called a foretaste of developments to come. Pfizer should have the results before the Food and Drug Administration later this month, said Dr. David Kimberlin, professor and co-director of UAB and Children’s of Alabama’s Division of Pediatric Infectious Diseases. “(Dr. Anthony) Fauci has said it would be authorized before Halloween,” he added. Pfizer said its study shows “a favorable safety profile and robust neutralizing antibody” for the 5-11 age group. The study gave Pfizer the results the company wanted to see, Kimberlin said. The study used one-third the adult dosage for children, which was selected for its safety, tolerability and immunogenicity, according to Pfizer. Read more.